Journal: Frontiers in Neurology
Article Title: Surrogate Cerebrospinal Fluid Biomarkers for Assessing the Efficacy of Gene Therapy in Hurler Syndrome
doi: 10.3389/fneur.2021.640547
Figure Lengend Snippet: Evaluation of each biomarker's predictive value for disease correction by quantitative immunoblotting. Equal concentrations of individual CSF samples ( n = 3) of healthy control dogs, untreated MPS I dogs, and early- and late-treated MPS I dogs were analyzed by Western blotting. Using ImageJ software, each band was scored semiquantitatively from 1 to 3 (1 = the value of the control). (A) Western blot images from each CSF sample for NP1, Ch3L1, CD14, and IGFBP2 proteins. (B) A color code indicates scores for each protein. An overall score (the average of the four protein scores) is shown in the bottom row. NP1, neuronal pentraxin 1; Ch3L1, chitinase 3-like 1; IGFBP2, insulin-like growth factor-binding protein 2; CD14, monocyte differentiation antigen CD14; Ctrl, healthy control; Et-MPS I, early-treated MPS I dogs; Lt-MPS I, late-treated MPS I dogs.
Article Snippet: The primary antibodies were rabbit antihuman neuronal pentraxin 1 (NP1, Sigma, Taufkirchen/Germany), rabbit antihuman insulin-like growth factor-binding protein 2 (IGFBP2, Thermo Scientific), rabbit antihuman chitinase-3-like 1 (Ch3L1, Biorbyt, Cambridge/UK), and mouse antihuman monocyte differentiation antigen CD14 (clone TÜK4, BioRad, Feldkirchen/Germany).
Techniques: Biomarker Discovery, Western Blot, Control, Software, Binding Assay